disodium;(2S,6aR,6aS,8aR,10S)-10-(3-carboxylatopropanoyloxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: disodium;(2S,6aR,6aS,8aR,10S)-10-(3-carboxylatopropanoyloxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylate
• 化学式: C34H48Na2O7
• 分子量: 614.7
• InChiKey: BQENDLAVTKRQMS-BJPJQFINSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -1.83
• 重原子数：
  43
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  124
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• Combinations of nootropic agents for treating cognitive dysfunctions
  申请人：Pharnext

  公开号：EP2705841A1

  公开（公告）日：2014-03-12

  The invention relates to compositions and methods for improving memory and related functions as alertness, attention, concentration, learning, and language processing. More particularly, the invention relates to compositions comprising at least two drugs selected from cinacalcet, baclofen, acamprosate, mexiletine, sulfisoxazole and torasemide useful to enhance memory and related functions in healthy subjects or subjects suffering from conditions or disorders having a negative impact on their memory.

  本发明涉及改善记忆和相关功能（如警觉性、注意力、集中力、学习和语言处理）的组合物和方法。更具体地说，本发明涉及由至少两种药物组成的组合物，这两种药物选自西那卡塞、巴氯芬、阿坎普罗斯酸、美西律汀、磺胺异噁唑和托拉塞米，这些药物有助于增强健康受试者或患有对其记忆力有负面影响的病症或紊乱的受试者的记忆力和相关功能。
• LEVOSIMENDAN FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS
  申请人：Pharnext

  公开号：EP3797767A1

  公开（公告）日：2021-03-31

  The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease and related disorders. In particular, the invention concerns compounds which, alone or in combination(s), can effectively modulate synapse function and/or angiogenesis and/or cell stress response. The invention also relates to methods of producing a drug or a drug combination for treating Alzheimer's disease and to methods of treating Alzheimer's disease or a related disorder.

  本发明涉及治疗阿尔茨海默病及相关疾病的组合物和方法。更具体地说，本发明涉及阿尔茨海默病及相关疾病的新型组合疗法。特别是，本发明涉及的化合物单独或组合使用可有效调节突触功能和/或血管生成和/或细胞应激反应。本发明还涉及治疗阿尔茨海默病的药物或药物组合的生产方法，以及治疗阿尔茨海默病或相关疾病的方法。
• Nootropic compositions for improving memory performance
  申请人：PHARNEXT

  公开号：US10265304B2

  公开（公告）日：2019-04-23

  The invention relates to compositions and methods for improving memory and related functions as alertness, attention, concentration, learning, and language processing. More particularly, the invention relates to compositions comprising at least two drugs selected from cinacalcet, baclofen, acamprosate, mexiletine, sulfisoxazole and torasemide useful to enhance memory and related functions in healthy subjects or subjects suffering from conditions or disorders having a negative impact on their memory.

  本发明涉及改善记忆和相关功能（如警觉性、注意力、集中力、学习和语言处理）的组合物和方法。更具体地说，本发明涉及由至少两种药物组成的组合物，这两种药物选自西那卡塞、巴氯芬、阿坎普罗斯酸、美西利汀、磺胺异噁唑和托拉塞米，这些药物有助于增强健康受试者或患有对其记忆力有负面影响的病症或紊乱的受试者的记忆力和相关功能。
• Compositions for treating neurological disorders
  申请人：PHARNEXT

  公开号：US10434109B2

  公开（公告）日：2019-10-08

  The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.

  本发明涉及治疗与谷氨酸兴奋毒性和淀粉样蛋白β毒性相关的神经系统疾病的组合物和方法。更具体地说，本发明涉及多发性硬化症、阿尔茨海默病、阿尔茨海默病相关疾病、肌萎缩侧索硬化症、帕金森病、亨廷顿病、神经性疼痛、酒精性神经病、酗酒或戒酒或脊髓损伤的新型组合疗法。
• Treatment of gynoid lipodystrophy
  申请人：Merz Pharma GmbH & Co. KGaA

  公开号：US11344573B2

  公开（公告）日：2022-05-31

  The present invention generally relates to the treatment of gynoid lipodystrophy, and more specifically to the use of calcium (hydroxy)phosphate particles in combination with at least one compound capable of reducing local subcutaneous fat in the treatment of gynoid lipodystrophy.

  本发明一般涉及妇科脂肪营养不良症的治疗，更具体地说，涉及将（羟基）磷酸钙颗粒与至少一种能够减少局部皮下脂肪的化合物结合使用，以治疗妇科脂肪营养不良症。